Source: Annual Congress 2011 - Lancet / ERS symposium - New frontiers in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. J. Martinez (Ann Arbor, United States of America). The future of COPD treatment: what are the difficulties in and barriers to drug development for COPD. Annual Congress 2011 - Lancet / ERS symposium - New frontiers in COPD

Member's Comments

No comment yet.

Related content which might interest you: The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement Source: Eur Respir J, 52 (5) 1801261; 10.1183/13993003.01261-2018 Year: 2018 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 It is time to further expand research in tailoring self-management of COPD exacerbations! Source: Eur Respir J, 55 (1) 1902225; 10.1183/13993003.02225-2019 Year: 2020 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 COPD self-management exacerbation action plans: predictors of adherence Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Importance of the initial behaviour of patients in avoiding late recovery from COPD exacerbations Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Early detection of asthma exacerbations and the use of action points for treatment decisions in self-management plans Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Evolving use of long-term NIV in COPD: Are we getting it right Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013 The future of disease monitoring and management: the homework for clinical researchers Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Is there a need for pharmacoepidemiology in asthma and COPD? Source: Annual Congress 2004 - Pharmacoepidemiology of obstructive lung disease: beyond clinical trials Year: 2004 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Facilitators and barriers of adherence to exacerbation action plans in patients with COPD and comorbidities: a qualitative study Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Challenges in COPD exacerbations and future research and unknowns Source: Annual Congress 2013 –Recommendations from the ERS/ATS Guideline on COPD Exacerbation Prevention Year: 2013